

Press release August 25th 2017

Oncopeptides AB Interim Report April - June 2017

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the second quarter 2017 report.

“It is gratifying that our pivotal Phase III study OCEAN commenced during the quarter, according to our strategic plan. This is a milestone for Ygalo[®] and for us as a company, and takes us one step closer to making Ygalo[®] available for late-stage multiple myeloma patients.” said Jakob Lindberg, CEO of Oncopeptides.

SUMMARY OF Q2

April 1st – June 30th 2017

- Net sales amounted to 0.0 (0.0) MSEK
- Loss for the period was 67.3 (loss: 23.5) MSEK
- Loss per share, before and after dilution, was 1.69 (loss: 1.19) SEK
- On June 30th cash and cash equivalents amounted to 535.1 (15.9) MSEK

Significant events during the period April 1st to June 30th 2017

- In June, the first patient was dosed in the pivotal phase III study OCEAN. The study is targeting Late-Stage Relapsed Refractory (RRMM) patients with Multiple Myeloma. The study is designed as a head-to-head comparative study where the result will show whether Ygalo[®] is more effective, just as effective, or less effective than the current standard of care treatment option pomalidomide for RRMM patients

FINANCIAL OVERVIEW OF THE GROUP (SEK thousand):

Financial overview of the group (SEK thousand)

	2017 Apr - Jun	2016 Apr - Jun	2017 Jan - Jun	2016 Jan - Jun	2016 Jan - Dec
Net sales	-	-	-	-	-
Operating loss	-67,260	-23,483	-129,343	-38,727	-114,482
Loss before tax	-67,260	-23,483	-129,343	-38,727	-114,446
Loss for the period	-67,260	-23,483	-129,343	-38,727	-114,446
Earnings per share before and after dilution (SEK)	-1.69	-1.19	-3.54	-2.01	-4.88
Cash flow from operating activities	-72,023	-19,538	-139,660	-32,669	-104,262
Cash and cash equivalents at the end of the period	535,069	15,919	535,069	15,919	40,251
Research & development costs/operating expenses %	74%	90%	75%	88%	78%

FINANCIAL CALENDAR

Interim Report Q3 2017
Full Year Report 2017

November 15th 2017
February 22nd 2018

For further information, please contact:

Jakob Lindberg, CEO for Oncopeptides AB
E-mail: jakob.lindberg@oncopeptides.se
Tel: +46 8 615 20 40

Rein Piir, Head of Investor Relations for Oncopeptides AB
E-mail: rein.piir@oncopeptides.se
Tel: +46 70 853 72 92

This information that Oncopeptides AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the persons above, 08.00 am CET on august 25th 2017.

About Oncopeptides

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company the focus has primarily been on the development of the lead product candidate Ygalo[®], an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. Ygalo[®] is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo[®] could potentially provide physicians with a new treatment option for patients suffering from this serious disease.